Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Non-cash Items (2022 - 2025)

Historic Non-cash Items for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $2.7 million.

  • Atara Biotherapeutics' Non-cash Items fell 8556.15% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 8556.15%. This contributed to the annual value of $172546.0 for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Atara Biotherapeutics' Non-cash Items stood at $2.7 million, which was down 8556.15% from $6.1 million recorded in Q2 2025.
  • Atara Biotherapeutics' 5-year Non-cash Items high stood at $47.4 million for Q1 2022, and its period low was $42000.0 during Q4 2022.
  • Moreover, its 4-year median value for Non-cash Items was $21.0 million (2023), whereas its average is $19.4 million.
  • Per our database at Business Quant, Atara Biotherapeutics' Non-cash Items surged by 2533478.26% in 2023 and then tumbled by 8556.15% in 2025.
  • Atara Biotherapeutics' Non-cash Items (Quarter) stood at $42000.0 in 2022, then skyrocketed by 55614.29% to $23.4 million in 2023, then plummeted by 99.26% to $172546.0 in 2024, then surged by 1464.8% to $2.7 million in 2025.
  • Its Non-cash Items was $2.7 million in Q3 2025, compared to $6.1 million in Q2 2025 and $8.6 million in Q1 2025.